- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Monheim, February 28, 2018 – Bayer fundamentally disagrees with EFSA’s updated risk assessment conclusions for the active substances imidacloprid and clothianidin. EFSA’s findings place it outside the current mainstream science on bee health, as represented by recent similar assessments done by agencies such as the U.S. EPA and Canadian PMRA. These assessments have shown conclusively that neonicotinoid products can be used by farmers to protect their valuable crops without harming honey bee colonies.
Unfortunately, EFSA chose to base its assessment on an unworkable guidance document that makes it impossible to field a study that would not find risk, despite repeated requests by Member States for a review of this guidance. EFSA’s conclusions can therefore not be used as a measuring stick to justify further neonicotinoid restrictions. While challenges to bee health remain due to a number of factors, the fact remains that the total number of beehives in the EU is continuing to rise. Bayer will continue to work with farmers, beekeepers and regulators on solutions that will have a positive impact on bee health.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 99,600 people and had sales of EUR 34.9 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.